OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients
Children's Health | Diseases of the Kidney & Urinary Tract
What is the purpose of this trial?
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.
- Ages12 - 17 years
- Trial withAllergan Sales, Inc.
- Start Date01/01/2015
- End Date12/30/2018
- Last Updated02/22/2018
- Study HIC#1409014633